@naultjc.bsky.social
📤 222
📥 236
📝 35
1) We recently published a multicentric study in
cghjournal.org/article/S154...
We analyzed using machine learning an international cohort of 1,399 pts treated for HCC with atezo/bev across 12 centers to uncover clinically meaningful subgroups.
@etrepo.bsky.social
loading . . .
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab
We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non‐a priori, data‐driven machine learning approach to uncover subgroups with distinct profiles acro...
https://cghjournal.org/article/S1542-3565(25)01002-X/fulltext
about 1 month ago
1
2
2
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with
@zucmanrossi.bsky.social
and
@markyarchoan.bsky.social
that you can find in
www.medrxiv.org/content/10.1...
loading . . .
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma
Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...
https://www.medrxiv.org/content/10.1101/2025.11.18.25340286v1
about 1 month ago
1
3
2
Claudia Campani from Cordeliers Research Center received Best clinical poster award in @ILCAnews meeting in Hong Kong
about 1 month ago
0
0
0
Claudia Campani presenting our work on Molecular based therapy in primary liver cancer refractory to systemic treatments in ILCA meeting in Hong Kong
about 1 month ago
0
1
0
Our work about « Molecular based targeted therapies in primary liver cancers » presented by Claudia Campani at ESMO precision medicine
@myesmo.bsky.social
4 months ago
0
2
0
Iron Maiden, Paris 2025
5 months ago
0
3
0
Kendrick Lamar/SZA Paris 2025
6 months ago
0
1
0
Neil Young, Paris 2025
6 months ago
0
2
0
reposted by
Nature Genetics
6 months ago
📢ONLINE
@natgenet.nature.com
📰Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers. By Tim Arnoldus, Daniel S. Peeper and colleagues. ⬇️
www.nature.com/articles/s41...
loading . . .
Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics
The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.
https://www.nature.com/articles/s41588-025-02221-2?utm_source=bluesky&utm_medium=social&utm_campaign=ng
1
4
1
Joe Satriani and Steve Vaï, Paris 2025
6 months ago
0
1
0
Pr Éric Trepo on genetic prédisposition to HCC on alcohol related liver Disease in the Paris Liver Cancer Group Day, June 2025
7 months ago
0
1
0
Paris Liver Cancer Group day, 19 June 2025.
7 months ago
0
0
0
Paris Liver Cancer Group day, 19 June 2025.
7 months ago
0
0
0
www.nature.com/articles/s41...
loading . . .
The pivot penalty in research - Nature
An analysis of millions of scientific papers and patents reveals a ‘pivot penalty’ when researchers shift direction, with the impact of studies decreasing rapidly the further they move from their prev...
https://www.nature.com/articles/s41586-025-09048-1
7 months ago
0
0
0
🧵1/ Can systematic biopsies during RFA improve how we diagnose & manage hepatocellular carcinoma (HCC)? Our study was recently published in J hep reports. Here's what we found 👇
www.jhep-reports.eu/article/S258...
loading . . .
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma
We aim to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).
https://www.jhep-reports.eu/article/S2589-5559(25)00107-7/fulltext
8 months ago
1
3
2
reposted by
Rob Brierley
10 months ago
Routine [18F]FCH and [18F]FDG PET-CT for tumour staging in all patients with a 1st diagnosis of hepatocellular carcinoma has limited clinical value Guidelines should continue to emphasise morphological imaging (eg MRI & CT) for staging
#OncSky
#MedSky
@oncoalert.bsky.social
@naultjc.bsky.social
add a skeleton here at some point
0
4
3
reposted by
The Lancet Gastroenterology & Hepatology
10 months ago
New research - Nault et al - [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study
https://buff.ly/419ebHP
#MedSky
#OncSky
#LiverSky
@naultjc.bsky.social
0
2
2
www.thelancet.com/journals/lan...
loading . . .
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of rand...
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00451-0/abstract
11 months ago
0
1
0
Fire walk with him
12 months ago
0
1
0
reposted by
Rob Brierley
12 months ago
New research - Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
www.thelancet.com/journals/lan...
#GastroSky
#OncSky
#MedSky
@oncoalert.bsky.social
0
9
7
www.nature.com/articles/s41...
loading . . .
Engineered extrachromosomal oncogene amplifications promote tumorigenesis - Nature
Large extrachromosomal DNAs are engineered using a CRISPR- and Cre–loxP-based approach and shown to drive cancer in mouse models, with potential applications in determining the role of oncogene a...
https://www.nature.com/articles/s41586-024-08318-8
about 1 year ago
0
0
0
www.nature.com/articles/s41...
about 1 year ago
0
2
1
aacrjournals.org/clincancerre...
about 1 year ago
0
0
0
you reached the end!!
feeds!
log in
